Latest Breaking News On - Zymeworks bc inc - Page 1 : vimarsana.com

5 Best Healthcare Stocks For the Long-Term

In this piece, we will take a look at the five best healthcare stocks for the long term.

Zymeworks Inc. (NYSE:ZYME) Q3 2023 Earnings Call Transcript

Operator: Good day, and thank you for standing by. Welcome to the Zymeworks Third Quarter 2023 Results Conference Call. At this time, all participants are in a listen-only mode.

ASCO: Targeted therapy induces responses in H

An MD Anderson-led Phase II trial showed the HER2-targeted therapy zanidatamab demonstrated durable responses in patients with advanced HER2-positive biliary tract cancer. The data were presented at the 2023 ASCO Annual Meeting.

Targeted Therapy Induces Responses in HER2-Amplified Biliary Tract Cancer, ASCO Reports

Targeted Therapy Shows Promise for HER2-Amplified Biliary Tract Cancer

Form 8-K Zymeworks Inc. For: May 17

Zymeworks Inc. (NYSE:ZYME) Q3 2022 Earnings Call Transcript

Operator: Ladies and gentlemen, thank you for standing by. This is conference operator. Welcome to Zymeworks Third Quarter 2022 Results Conference Call and Webcast.

Jazz (JAZZ) and Zymeworks (ZYME) Enter License Agreement to Develop and Commercialize Zanidatamab

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody

Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan Zymeworks to receive $50 million upfront payment, a second payment

Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody

Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan Zymeworks to receive $50 million upfront...